Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News

Welcome to the Cambridge Angels

Home
About Us
Who we are
Founders and Chairs
Individual Members
Emeritus Members
Corporate and Research Members
Cambridge Angels Team
Infographic
Entrepreneurs
Why Cambridge Angels?
Is Angel Investing right for you?
Investment Criteria
Application Process
Apply
Angels
Membership Information
Member portal
Angel Interviews
Portfolio
Current Portfolio
Exits
Cambridge Angels Founded Companies
Portfolio facts
Portfolio Interviews
Apply to Cambridge Angels
News
Portfolio News
Ecosystem News
Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials
5 September 2022
Cambridge Angels
Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials
Cambridge Angels
5 September 2022

Qureight announces world’s first digital biomarker for lung fibrosis will ‘transform’ clinical trials

Cambridge Angels
5 September 2022

Source:pmlive.com/pharma_news/qureight_announces_worlds_first_digital_biomarker_for_lung_fibrosis_will_transform_clinical_trials_1454442

Newer PostPhoreMost in drug target discovery collaboration with Roche
Older PostPsyomics links up with Hertfordshire Partnership University NHS Foundation Trust
LI-In-Bug_small.png
Back to Top
Privacy
info@cambridgeangels.net